- Free Express Shipping on Orders $200+
- Get Premium-Grade Peptides and Save When You Buy in Bundles
- Made in the USA
$164.99
GKP BLEND from Epic Peptides Lab is a research-use-only compound supplied in a preloaded 3ml Disposable Self-injection Pen at 70mg/ml for laboratory study, offering consistent measured delivery and reliable handling for researchers.
Epic Peptides Lab · Research Use Only
GHK-Cu + BPC-157 + KPV in solution · 3ml at 70mg/ml
The GKP blend Disposable Self-injection Pen is a preloaded 3ml research device holding GHK-Cu, BPC-157 and KPV in solution at 70mg/ml. Total peptide comes to 210mg. The vial equivalent is supplied at a documented 50/10/10 split, which makes this one of the few blend devices where the composition can be inferred with some confidence.
| Property | Value |
|---|---|
| Device format | Preloaded Disposable Self-injection Pen , glass cartridge |
| Fill volume | 3 ml |
| Concentration | 70 mg/ml total peptide |
| Total peptide in device | 210 mg |
| Components | GHK-Cu, BPC-157, KPV |
| Vial equivalent composition | GHK-Cu 50mg, BPC-157 10mg, KPV 10mg per 70mg |
| Device composition | Not stated on the product record. If scaled from the vial ratio, approximately 150mg, 30mg and 30mg |
| CAS, GHK-Cu | 89030-95-5 |
| CAS, BPC-157 | 137525-51-0 |
| CAS, KPV | 67727-97-3 |
| MW, GHK-Cu | 401.91 g/mol |
| MW, BPC-157 | 1419.55 g/mol |
| MW, KPV | 342.43 g/mol |
| Target, GHK-Cu | Copper(II) coordination, fibroblast collagen synthesis |
| Target, BPC-157 | VEGFR2 with downstream Akt and eNOS activation |
| Target, KPV | NF-κB signalling via PepT1 uptake |
| Solution appearance | Clear blue to blue-violet |
| Reconstitution required | None |
| Excipient system | Not published on the product record |
| Solution stability | Not established over device shelf life |
| Storage | 2-8°C, protected from light |
| Purity | Per lot-specific certificate of analysis |
| Regulatory status | No approved human or veterinary formulation for any component |
Partially, and the GKP blend Disposable Self-injection Pen is unusual in that respect, because the vial equivalent publishes its split while most blends do not.
The GKP vial is documented at 50mg GHK-Cu, 10mg BPC-157 and 10mg KPV, totalling 70mg. If the device at 70mg/ml scales that ratio proportionally across 3ml, the contents would be approximately 150mg GHK-Cu, 30mg BPC-157 and 30mg KPV.
The word if is doing real work in that sentence. Nothing on the product record states that the device uses the same ratio, and manufacturers sometimes reformulate for solution stability rather than replicating a lyophilized composition exactly. A copper-containing solution in particular might justify a different balance.
Treat the inferred figures as a hypothesis awaiting confirmation, not as specification. Where a study depends on knowing the actual composition, an inference of this kind is simply not good enough to build on.
Assuming the vial ratio holds across formats, the molar disparity between components turns out to be substantial.
At 401.91 daltons, 150mg of GHK-Cu works out at roughly 373 micromoles of material. Thirty milligrams of BPC-157 at 1419.55 is approximately 21 micromoles. Thirty milligrams of KPV at 342.43 is approximately 88 micromoles.
GHK-Cu therefore outnumbers BPC-157 by roughly eighteen to one on a molar basis, and KPV by roughly four to one. The copper tripeptide dominates numerically as thoroughly as it does by mass.
Those are the numbers to normalise against when comparing with single-component preparations. Not the 70mg/ml label. Every one of those figures stays provisional until the composition is confirmed.
The copper component is the reason, and the mechanism is specific rather than general.
Copper(II) absorbs visible light, which is why the solution is blue. Absorbed energy can drive photoreduction to copper(I), and copper(I) with dissolved oxygen participates in Fenton-type chemistry producing hydroxyl radicals. Those radicals attack indiscriminately.
Composition determines who is exposed. Neither BPC-157 nor KPV contains cysteine, methionine, tryptophan, tyrosine or histidine, the five residues most susceptible to that chemistry. BPC-157 runs Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. KPV is three residues, Lys-Pro-Val.
On sequence grounds this is a comparatively favourable combination to hold in a copper-containing solution, considerably more so than the GLOW and KLOW blends which both include thymosin β4 and its methionine. That is an inference from composition rather than a stability measurement, and it does not substitute for one.
For the GKP blend Disposable Self-injection Pen, colour is the first and cheapest check. Clear blue to blue-violet is expected. Fading toward colourless indicates the GHK-Cu component has lost copper, and a shift toward green or brown indicates uncharacterised chemistry.
Inspect against dark and light backgrounds alike. Aggregation shows as faint opalescence long before obvious turbidity, and only a dark background reveals that early stage.
Gravimetric verification establishes actual delivered volume. Actuate onto a tared vessel, record mass, convert by solution density, repeat across several actuations for accuracy and precision. Perform it at the temperature of intended use, because cold solution is more viscous and viscosity changes delivery in a spring mechanism.
Throw away that first actuation instead of recording it as data. Air entering the delivery path, and seals relaxing during storage, both under-deliver on that first actuation.
The GKP pairing is unusual in this catalogue because both formats exist and the vial publishes its composition, which makes the comparison unusually concrete.
The vial arrives lyophilized, split 50/10/10 across 70mg, and documented as such on the product record. Reconstituting it introduces the familiar variability: diluent measurement, incomplete dissolution, shear, adsorptive loss during transfer. Three components dissolving together makes incomplete dissolution a real risk, since one under-dissolved component shifts the composition invisibly.
The device removes all of that and fixes concentration at manufacture, at the cost of solution-state storage from that point onward.
For this particular combination the solution-state cost is lower than for GLOW or KLOW. Neither BPC-157 nor KPV contains any of the residues most vulnerable to copper-catalysed oxidation, so the copper component has less to attack than it would alongside thymosin β4 and its methionine.
The deciding factor is usually study duration. A short intensive programme favours the device. Work spread across many months favours reconstituting vials as needed, since accumulated time in solution is the variable that grows.
Three of them. Naming them openly is more useful than implying the record is complete.
Whether the device actually replicates that vial ratio remains unconfirmed. The inference is reasonable. If it is wrong, every molar calculation shifts.
The excipient system is unpublished. Whatever it contains travels into any downstream assay the drawn solution joins. For a copper-containing formulation, the presence of an antioxidant or chelator is no trivial detail.
Shelf-life stability is unpublished, leaving device lifetime to be set by policy rather than data.
None of these gaps is unusual for research-format material of this kind. All three are reasonable to request and unreasonable to assume, and a laboratory depending on any of them should ask before rather than after.
Hold the device at 2-8°C away from light. Return it to its packaging between sessions. Light exclusion here addresses one specific photochemical route through copper, not a general precaution.
Let the device equilibrate to ambient temperature before actuating, and inspect it before every single draw.
Where the drawn solution enters a buffered downstream system, check that buffer for chelating agents. EDTA will strip copper from the GHK-Cu component regardless of how carefully the device itself was handled, and the findinging failure presents as an inactive compound rather than as a buffer problem.
Record device lot, date of first actuation, storage conditions and volume drawn each session. With shelf-life stability unpublished, the interval between first use and each later draw is a variable that belongs in the data record.
Because shelf-life data is unpublished, the record substitutes for it, and that makes documentation more consequential here than for a lyophilized vial.
Write the date of first actuation on the device itself. Marker on the barrel does the job, and it settles any later question about service life.
Log the lot number, storage conditions and volume drawn each session, together with a note on how the solution looked at the time.
Where a device spans more than one experimental series, note which series drew from which device. A finding that later looks anomalous can then be checked against device age rather than being unexplainable.
Cross-checked against publisher records or primary indexes. Each covers one component, and none covers the combination or this particular delivery format.
What is the GKP blend Disposable Self-injection Pen?
A preloaded 3ml research device containing GHK-Cu, BPC-157 and KPV in solution at 70mg/ml, giving 210mg total. No reconstitution is required. Supplied for laboratory research use only and not approved for human or veterinary use in any jurisdiction.
What is in the device?
The same three compounds as the GKP vial. The vial publishes a 50mg, 10mg and 10mg split across 70mg total. If the device scales that ratio proportionally, contents would be roughly 150mg GHK-Cu, 30mg BPC-157 and 30mg KPV, though nothing on the record confirms this.
Can the composition really be inferred?
Only provisionally, and the distinction matters more than it might appear. Manufacturers sometimes reformulate for solution stability rather than replicating a lyophilized composition exactly, and a copper-containing solution could easily justify a different balance. Treat the inferred figures as a hypothesis requiring confirmation.
What does the molar composition look like?
Assuming the vial ratio carries across, roughly 373 micromoles of GHK-Cu against 21 of BPC-157 and 88 of KPV. GHK-Cu outnumbers BPC-157 by around eighteen to one. It dominates the preparation numerically as thoroughly as it does by mass.
Why does copper matter in solution?
Copper(II) absorbs visible light, and absorbed energy can drive photoreduction to copper(I), which with dissolved oxygen participates in Fenton-type chemistry producing hydroxyl radicals. Those radicals attack indiscriminately. Light exclusion here is therefore specific rather than generic.
Is this a favourable combination to hold in solution?
On composition grounds, comparatively yes. Neither BPC-157 nor KPV contains a single one of the five residues most susceptible to copper-catalysed oxidation. GLOW and KLOW both carry thymosin beta 4 and its methionine, which changes the picture considerably.
How should the device be verified?
Begin with colour. Clear blue to blue-violet is expected, and fading points to copper loss from the tripeptide. Inspect against a dark background as well, since aggregation appears as faint opalescence before turbidity. Then confirm delivered volume gravimetrically across several actuations.
Why discard the first actuation?
Air ingress into the delivery path and seal relaxation both cause under-delivery on the first actuation after a rest period. Unless a priming step is specified and followed, that first draw should be discarded rather than measured, since it will not represent the device performance.
Does buffer choice still matter with a device?
Yes, downstream. EDTA and other chelators in any buffer the solution enters will strip copper from the GHK-Cu component regardless of how carefully the device was handled. The failure presents as an inactive compound rather than a buffer problem. That makes it easy to misdiagnose.
How does this compare with the GKP vial?
Same three compounds in a different physical state, and the trade-off runs both ways. The vial ships lyophilized, suppressing degradation, but requires reconstitution and the variability that introduces. The device removes reconstitution entirely and accepts solution-state storage from manufacture onward instead.
How does the device compare with the GKP vial?
The vial arrives lyophilized at a documented 50/10/10 split and requires reconstitution, which introduces measurement error, incomplete dissolution, shear and adsorptive loss. The device removes all of that and fixes concentration at manufacture, accepting solution-state storage in exchange.
Is solution storage riskier for this blend than for GLOW?
Less so. Neither BPC-157 nor KPV contains any of the residues most vulnerable to copper-catalysed oxidation, so the copper component has less to attack here than it would alongside thymosin beta 4 and its methionine, which both GLOW and KLOW contain.
Which format should a long study use?
Vials, generally. Accumulated time in solution is the variable that grows with study duration, so work spread across many months favours reconstituting as needed. Short intensive programmes favour the device and its between-session consistency.
What should be written on the device itself?
The date of first actuation, in marker on the barrel, which costs nothing and settles any later question about service life. Shelf-life data for this formulation is unpublished. That absence makes the written date the only reliable record of how long a device has been open.
How should device use be logged?
Lot number, storage conditions, volume drawn each session, and the appearance of the solution on that occasion. Where a device spans more than one experimental series, note which series drew from which device so an anomaly can be checked against device age.
The GKP blend Disposable Self-injection Pen is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
The same verification the labs that use our compounds demand — documented, transparent, and enforced on every order.
Independent HPLC and mass-spec testing confirms identity and purity on every batch.
A full certificate of analysis is published and downloadable for every lot we ship.
Tracked, discreet packaging with reshipment coverage on qualifying orders.
Orders confirmed before 12 PM PT on business days ship the same day from our US-based facility.
Enter your details to access our catalog, COA library,
and research compound database.
By submitting you agree to receive email communications from Epic Peptides Lab You can unsubscribe at any time. All products for in vitro research use only.
Restock alerts, new compounds and fresh lab results.
We’ll email your code straight away – 15% off, one-time use.
Research updates only. Unsubscribe any time.
Reviews
There are no reviews yet.